Efficacy of L-Carnitine for Dilated Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials

Weng, Yuanyuan; Zhang, Shuo; Huang, Wei; Xie, Xianze; Ma, Zhiyuan; Fan, Qiaomei

doi:10.1155/2021/9491615

Cited by 5 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies have also shown that supplementation of Levocarnitine, an amino acid-derived molecule, boosts energy metabolism in cardiomyocytes by promoting myocardial fatty acid oxidation [ 28 , 29 ]. Cardioprotective effects of L-carnitine also include inhibition of cardiac fibrosis, nitric oxide generation, and interstitial myocardial remodeling [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Familial dilated cardiomyopathy in a child: a case report

Ismail,

Khreis,

Assaad

et al. 2024

BMC Pediatr

View full text Add to dashboard Cite

Background Dilated cardiomyopathy (DCM) commonly leads to heart failure (HF) and represents the most common indication for cardiac transplantation in the pediatric population. Clinical manifestations of DCM are mainly the symptoms of heart failure; it is diagnosed by EKG, chest x-ray and echocardiography. For the idiopathic and familial diseases cases of DCM, there are no definite guidelines for treatment in children as they are treated for prognostic improvement. Case presentation We report the case of a 2-year-old girl diagnosed with dilated cardiomyopathy associated with homozygous mutation in the Myosin Light Chain 3 gene admitted for edema in lower extremities, muscle weakness, lethargy and vomiting, and she was found to be in cardiogenic shock. Chest x-ray showed cardiomegaly and EKG showed first degree atrioventricular block. Echocardiogram showed severe biventricular systolic and diastolic dysfunction. After 70 days of hospitalization, the patient went into cardiac arrest with cessation of electrical and mechanical activity of the heart, despite cardiopulmonary resuscitative efforts. Conclusion Although rare, pediatric DCM carries a high risk of morbidity and mortality and a lack of curative therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Familial dilated cardiomyopathy in a child: a case report

Ismail,

Khreis,

Assaad

et al. 2024

BMC Pediatr

View full text Add to dashboard Cite

show abstract

“…Multiple studies have also shown that supplementation of Levocarnitine, an amino acid-derived molecule, boosts energy metabolism in cardiomyocytes by promoting myocardial fatty acid oxidation [29][30] . Cardioprotective effects of L-carnitine also include inhibition of cardiac brosis, nitric oxide generation, and interstitial myocardial remodeling 31 .…”

Section: Discussionmentioning

confidence: 99%

Familial Dilated Cardiomyopathy in a Child: A Case Report

Ismail,

Khreis,

Assaad

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Dilated cardiomyopathy (DCM) commonly leads to heart failure (HF) and represents the most common indication for cardiac transplantation in the pediatric population. Clinical manifestations of DCM are mainly the symptoms of heart failure; it is diagnosed by EKG, chest x- ray and echocardiography. For the idiopathic and familial diseases cases of DCM, there are no definite guidelines for treatment in children as they are treated for prognostic improvement. Case presentation We report the case of a 2-year-old girl diagnosed with dilated cardiomyopathy associated with homozygous mutation in the Myosin Light Chain 3 gene admitted for edema in lower extremities, muscle weakness, lethargy and vomiting, and she was found to be in cardiogenic shock. Chest x-ray showed cardiomegaly and EKG showed first degree atrioventricular block. Echocardiogram showed severe biventricular systolic and diastolic dysfunction. After 70 days of hospitalization, the patient went into cardiac arrest with cessation of electrical and mechanical activity of the heart, despite cardiopulmonary resuscitative efforts. Conclusion Although rare, pediatric DCM carries a high risk of morbidity and mortality and a lack of curative therapy.

show abstract

“…L-carnitine is an endogenous amino acid that has an important role in myocardial fatty acid metabolism and energy production [12]. It was reported to improve cardiac function in patients with chronic heart failure and dilated cardiomyopathy [13,14] and to have myocardial protective effects in rheumatic valvular surgery and coronary artery bypass graft (CABG) in adults [15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

L-carnitine decreases myocardial injury in children undergoing open-heart surgery: A randomized controlled trial

El Feky,

El-Afify,

Abdelhai

et al. 2024

Eur J Pediatr

View full text Add to dashboard Cite

Myocardial injury in open-heart surgery is related to several factors including ischemia–reperfusion injury, generation of reactive oxygen species, increased production of inflammatory mediators, and enhancement of apoptosis of cardiomyocytes. The aim of this study was to study the effect of L-carnitine on myocardial injury in children undergoing open-heart surgery. This clinical trial was performed on 60 children with congenital heart disease (CHD) who underwent open-heart surgery. They were randomized into two groups: L-carnitine group who received L-carnitine 50 mg\kg\day once daily for 1 month before cardiac surgery and control group who received placebo for 1 month before cardiac surgery. Left ventricular cardiac function was assessed by conventional echocardiography to measure left ventricular ejection fraction (LVEF) and two-dimensional speckle tracking echocardiography (2D-STE) to determine left ventricular global longitudinal strain (2D-LV GLS). Blood samples were obtained pre-operatively at baseline before the administration of L-carnitine or placebo and 12 h post-operatively to measure the level of malondialdehyde (MDA), superoxide dismutase (SOD), fas, caspase-3, creatinine kinase-MB (CK-MB), and troponin I. L-carnitine group had significantly lower post-operative level of oxidative stress marker (MDA), apoptosis markers (fas and caspase-3), and myocardial injury markers (CK-MB and troponin I), but they had significantly higher SOD post-operative level compared to the control group. In addition, post-operative LVEF and 2D-LVGLS were significantly lower in the control group compared to L-carnitine group. Conclusion: L-carnitine can reduce myocardial injury, improve post-operative left ventricular cardiac function, and may provide myocardium protection in children with CHD who underwent open-heart surgery. Trial registration: The clinical trial was registered at www.pactr.org with registration number PACTR202010570607420 at 29/10/2020 before recruiting the patients. What is Known:• Myocardial injury in open-heart surgery is related to several factors including ischemia–reperfusion injury, generation of reactive oxygen species, increased production of inflammatory mediators, and enhancement of apoptosis of cardiomyocytes.• L-carnitine was reported to have myocardial protective effects in rheumatic valvular surgery and coronary artery bypass graft (CABG) in adults; however, there is no evidence on its effectiveness in children undergoing open-heart surgery. What is New:• L-carnitine significantly lowered the post-operative level of oxidative stress marker (MDA), apoptosis markers (fas and caspase-3), and myocardial injury markers (CK-MB and troponin I) in the treatment group.• L-carnitine can reduce myocardial injury, improve post-operative left ventricular cardiac function, and may provide myocardium protection in children with CHD who underwent open-heart surgery.

show abstract

Efficacy of L-Carnitine for Dilated Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials

Cited by 5 publications

References 26 publications

Familial dilated cardiomyopathy in a child: a case report

Familial dilated cardiomyopathy in a child: a case report

Familial Dilated Cardiomyopathy in a Child: A Case Report

L-carnitine decreases myocardial injury in children undergoing open-heart surgery: A randomized controlled trial

Contact Info

Product

Resources

About